Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Right Dose, Right Now
NL-OMON29254Not yet recruiting
- Sponsor
- VU University Medical Center
- Start
- Oct 2017
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vancomycin, ceftriaxone, meropenem, ciprofloxacin and cefotaxime in sepsis and Infection, sponsored by VU University Medical Center. Primary endpoint: PK target attainment in the first 24 hours. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
vancomycinceftriaxonemeropenemciprofloxacincefotaxime
03
Conditions
sepsisInfection
Beyond the preview
Go deeper on NL-OMON29254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29254.